Part 2. Learning levodopa with the body
Levodopa is an old drug.
Yet the longer you live with Parkinson’s disease, the more complicated this old drug becomes.
The textbook explanation is simple.
Dopamine cannot adequately cross the blood–brain barrier.
So we give its precursor, levodopa.
Levodopa enters the brain, is converted to dopamine, and supplements the failing dopamine function.
But what the patient really wants to know comes next.
So — when will my body move?
You take the dose.
You wait.
It comes up.
You move well.
Sometimes it does not come up enough.
Sometimes it comes up too late.
And then it falls again.
I began to see levodopa not as the name of a drug but as a curve that moves through time.
Chapter 4. Why levodopa still matters
In Parkinson’s disease, the loss of dopamine neurons in the substantia nigra reduces dopamine function in the striatum.
Swallowing dopamine itself does not solve this, because dopamine does not cross the blood–brain barrier effectively.
So we use the precursor, levodopa, which can cross the barrier and be converted to dopamine inside the brain.
But there is a catch.
If levodopa is converted to dopamine in the periphery before it reaches the brain, less of it gets in.
That is why real formulations usually combine it with a peripheral dopa-decarboxylase inhibitor such as carbidopa or benserazide.
Thanks to this combination, more levodopa reaches the brain and peripheral side effects are reduced.
Yet this principle alone does not decide the patient’s day.
How much was absorbed, how fast it rose, and what state the body was in at that moment — these act together.
Chapter 5. Taking the pill does not instantly make dopamine
From swallowing one levodopa tablet to reaching a good ON, many steps intervene.
Ingestion → passing the stomach → reaching the small intestine → absorption → rising plasma levodopa → crossing the blood–brain barrier → conversion to dopamine in the brain → change in the basal ganglia circuits → change in movement
If any one of these steps runs late, the ON the patient feels runs late.
So recording only the time of the dose is not enough.
I began tracking three separate times.
The time of the dose.
The time the first sign appeared.
The time a genuinely sufficient ON was reached.
Even with the same 100 mg, when the gaps between these three times change, the drug the body experiences feels entirely different.
Chapter 6. Rise fast, or last long?
Using levodopa formulations, you meet two competing goals.
One is:
“I want it to come up fast.”
The other:
“I want it not to fall for a long time.”
In a deep morning OFF, when the first effect arrives may matter more than how long it lasts.
Conversely, during hours when you are already moving reasonably, holding the trough until the next dose may matter more than building a fast, high peak.
So immediate-release and extended-release forms are hard to understand as simply a “strong drug” versus a “weak drug.”
The better question is:
Which part of my curve is this formulation trying to change?
Does it speed the rise?
Does it change the peak?
Does it extend the duration?
Does it support the trough?
A drug’s role does not show up in the dose alone.
Chapter 7. Delayed ON — I took the dose; why isn’t it coming up?
One of the most frustrating moments is when you take the dose and nothing happens.
Thirty minutes.
Forty minutes.
An hour passes.
The body is still heavy.
Naturally, a thought follows:
“Is the dose too small?”
Not necessarily.
Levodopa is absorbed in earnest only after it reaches the small intestine.
So if gastric emptying is slow, the onset of effect can be slow.
Meals can matter too.
Large neutral amino acids in particular can compete with levodopa at the transport steps in the gut and at the blood–brain barrier.
The gastrointestinal changes of Parkinson’s disease itself can also play a part.
So the same drug at the same dose does not turn ON at the same time every day.
This is the key point about Delayed ON:
A dose that is missing and a dose that has not yet arrived are different things.
Chapter 8. Wait, or take more?
Delayed ON is hard because, to the patient, both situations feel identically like OFF.
A dose that is genuinely insufficient feels like OFF.
A dose that has not yet been absorbed also feels like OFF.
But the responses are not the same.
If the earlier dose is merely absorbing late and an extra dose is added on top, the two curves can rise together late and build a higher peak than expected.
OFF → long delay → abrupt rise → high peak → dyskinesia
That shape is possible.
So when the effect is late, before asking “how many more mg,” I learned to ask:
“Is it insufficient right now, or is it still on its way up?”
This is not an argument for self-adjusting doses.
It is exactly the reason to record delayed responses and confirm the pattern.
Chapter 9. Incomplete ON — it came up, but not enough
There is a more ambiguous state.
The drug is not failing entirely.
The body clearly improved a little.
But it never climbs to the good ON that you know.
Think of it in output.
You start at 20.
It becomes 30.
Then 40.
It reaches 50.
The body is somewhat easier, but not enough.
I came to understand this state as incomplete ON.
It is hard to express with the two words ON and OFF alone.
Ask “did the medication work?” and the answer turns vague:
It worked — but not enough.
This is one reason I came to value a continuous record of output.
Chapter 10. ON failure — the day the threshold is never crossed
There is a case more extreme than incomplete ON.
You take the dose.
You wait.
There seems to be some change, but a sufficient ON is never reached.
Time passes, and the next dose draws near.
This situation can be seen through the lens of ON failure.
Here too, you cannot simply conclude “the drug was weak.”
It could be absorption.
It could be related to a meal.
The gut may be in a different state that day.
The starting point left by the previous dose’s curve can also matter.
So what matters more than a single ON failure is the repeating pattern.
Does it repeat in the mornings?
Does it repeat after particular meals?
Does it repeat with a particular formulation?
Did the first sign come but the threshold was never crossed?
Only by overlaying many records can you begin to tell chance from pattern.
Chapter 11. Wearing-off — is it only that the drug got shorter?
Early in the disease, one levodopa dose can carry you stably for a long stretch.
With time, the body begins to fall before the next dose is due.
Wearing-off.
Patients often put it this way:
“It used to last four hours. Now it doesn’t even last three.”
But it is hard to attribute this only to a sudden change in the drug’s half-life.
As the disease progresses, the dopamine system’s capacity to store and buffer declines, and swings in plasma levodopa are reflected more directly in the motor state.
Where the body once tolerated a fair range of concentration change, smaller changes now show up as sharper ON and OFF.
I find it intuitive to picture this as a curve that has lost its buffer.
Small waves in plasma concentration begin to appear as larger waves in the body’s output.
Chapter 12. The same 100 mg does not produce the same effect
Of everything I learned taking levodopa over the years, this is the clearest:
The same 100 mg is not always the same 100 mg.
The number on the prescription is identical, but the starting point differs.
How much of the previous dose’s effect remains differs.
Gastric emptying differs.
Meals differ.
Sleep, exercise, and the state of the bowels differ.
And there is no guarantee the brain receives the same concentration the same way on any given day.
That is why I concluded that recording the amount alone is not enough.
The dose is close to an input; the output is close to a result.
Between the two lies time.
And within that time, absorption and distribution, the blood–brain barrier, dopamine conversion, the basal ganglia circuits, food, and gut motility all act together.
Closing Part 2
At first I thought levodopa therapy was a question of how many mg to take.
Watching my body over time, the question changed.
How fast does it rise?
How high does it reach?
How long does it hold?
When does it begin to fall?
How much of the previous effect remains when the next dose comes up?
In the end, levodopa therapy was not about a single tablet’s dose.
It was closer to reading the whole day’s curve.
And once you start seeing that curve, the single sentence “the medication didn’t work today” splits into several questions.
Did it work late?
Did it fail to rise enough?
Did it never cross the threshold at all?
Did it fall too fast?
From the moment you can tell these apart, levodopa stops being a mere tablet and starts to look like a drug that moves through time.
This article is for education, to help understand how medication response changes in Parkinson’s disease. Any change to an individual’s medication type, dose, or timing should be discussed with the treating clinician.